Neoadjuvant pyrotinib plus trastuzumab, and chemoterapy in patients with HER2-positive early breast cancer: a real-world study

被引：0
|
作者：
Zhou, Jun
Wang, Rui
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO2-01-05
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO2-01-05
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Real-world outcomes and safety of pyrotinib in HER2-positive metastatic breast cancer (MBC) patients: A prospective cohort study
    Luo, T.
    Zhang, Q.
    He, P.
    Zhong, X.
    Yan, X.
    Tian, T.
    Huang, J.
    Zhang, Z.
    Zheng, H.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S490 - S490
  • [22] Phase II study of pyrotinib plus albumin-bound paclitaxel and trastuzumab as neoadjuvant treatment in HER2-positive early or locally advanced breast cancer
    Luo, T.
    Zhong, X.
    He, P.
    Yan, X.
    Tian, T.
    Wei, B.
    Zhang, Z.
    Li, J.
    Zheng, H.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S331 - S331
  • [23] Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study
    Cil, Ibrahim
    Kucukarda, Ahmet
    Atci, Muhammed Mustafa
    Secmeler, Saban
    Paksoy, Nail
    Ferhatoglu, Ferhat
    Ak, Naziye
    Ayhan, Murat
    Ozyukseler, Deniz Tataroglu
    Onder, Arif Hakan
    Avci, Okan
    Oyman, Abdilkerim
    Okten, Ilker Nihat
    Gulturk, Ilkay
    Akagunduz, Baran
    Basoglu, Tugba
    Cakir, Emre
    Hacibekiroglu, Ilhan
    Ozcelik, Melike
    Aydiner, Adnan
    [J]. TUMORI JOURNAL, 2022, 108 (01): : 19 - 25
  • [24] Pyrotinib and Trastuzumab Plus Chemotherapy Serve as an Acceptable Neoadjuvant Regimen Exhibiting Good Efficacy and Tolerance in HER2-Positive Breast Cancer Patients
    Chen, Yibo
    Zhang, Tianyi
    Zhang, Rui
    Cao, Xuchen
    [J]. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2024, 39 (06) : 435 - 440
  • [25] Neoadjuvant pyrotinib plus trastuzumab and nab-paclitaxel for HER2-positive early or locally advanced breast cancer: an exploratory phase II trial
    Zhong, Xiaorong
    He, Ping
    Chen, Jie
    Yan, Xi
    Wei, Bin
    Zhang, Zhang
    Bu, Hong
    Li, Jing
    Tian, Tinglun
    Lv, Qing
    Wang, Xiaodong
    Li, Hongjiang
    Wang, Jing
    Huang, Juan
    Suo, Jiaojiao
    Liu, Xiaoxiao
    Zheng, Hong
    Luo, Ting
    [J]. GLAND SURGERY, 2022, 11 (01) : 216 - +
  • [26] Real-world evidence regarding the efficacy and toxicity of neoadjuvant trastuzumab and pertuzumab in the management of HER2-positive early-breast cancer.
    Hall, Benjamin James
    Bhojwani, Ajay Ashok
    Innes, Helen
    Ahmed, Eliyaz
    Cliff, Joanne
    Malik, Zaf
    O'Hagan, Julie Elizabeth
    Tolan, Shaun
    Hall, Allison
    Hayat, Khizar
    Errington, Douglas
    Alam, Farida
    Thorp, Nicky
    Flint, Helen
    Law, Andrea
    Wong, Helen
    O'Reilly, Susan
    Jackson, Richard
    Cicconi, Silvia
    Palmieri, Carlo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [27] Efficacy and safety of pyrotinib-containing regimen in the patients with HER2-positive metastatic breast cancer: A multicenter real-world study
    Yin, Sha
    Chi, Yajing
    Du, Yangyang
    Wang, Jingfen
    Shan, Changping
    Yi, Weiwei
    Shang, Mao
    Man, Xiaochu
    Tan, Qiaorui
    Li, Huihui
    [J]. CANCER MEDICINE, 2023, 12 (03): : 2333 - 2344
  • [28] Pyrotinib in HER2-Positive local advanced or metastatic breast cancer patients: Results from a retrospective study in real-world setting
    Wang, Q.
    Chen, C.
    Wang, Y.
    Sun, S.
    Cheng, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2020, 138 : S58 - S58
  • [29] Effectiveness and safety of pyrotinib-based therapy in patients with HER2-positive metastatic breast cancer: A real-world retrospective study
    Li, Chao
    Bian, Xiaoli
    Liu, Zhaoyun
    Wang, Xinzhao
    Song, Xiang
    Zhao, Wei
    Liu, Yansong
    Yu, Zhiyong
    [J]. CANCER MEDICINE, 2021, 10 (23): : 8352 - 8364
  • [30] Safety and efficacy analysis of neoadjuvant pertuzumab, trastuzumab and standard chemotherapy for HER2-positive early breast cancer: real-world data from NeoPowER study
    Canino, Fabio
    Barbolini, Monica
    De Giorgi, Ugo
    Fontana, Tommaso
    Gaspari, Valeria
    Gianni, Caterina
    Gianni, Lorenzo
    Maestri, Antonio
    Minichillo, Santino
    Moscetti, Luca
    Mura, Antonella
    Nicoletti, Stefania Vittoria Luisa
    Omarini, Claudia
    Pagani, Rachele
    Sarti, Samanta
    Toss, Angela
    Zamagni, Claudio
    Costantini, Riccardo Cuoghi
    Caggia, Federica
    Antonelli, Giuseppina
    Baglio, Federica
    Belluzzi, Lorenzo
    Martinelli, Giulio
    Natalizio, Salvatore
    Ponzoni, Ornella
    Dominici, Massimo
    Piacentini, Federico
    [J]. BMC CANCER, 2024, 24 (01)
12345